Robert A. Holton
From Wikipedia, the free encyclopedia
University of North Carolina
Robert Holton | |
|---|---|
| Born | January 26, 1944 |
| Died | May 21, 2025 (aged 81) Tallahassee, Florida, U.S. |
| Education | Florida State University, PhD |
| Alma mater | Florida State University University of North Carolina |
| Occupation(s) | chemist and professor |
| Known for | Holton Taxol total synthesis Florida Inventors Hall of Fame |
| Spouse | married twice |
| Children | 3 |
Robert Anthony Holton (January 26, 1944 – May 21, 2025) was an American chemist and academic renowned for his pioneering work in the chemical synthesis of the anti-cancer drug Taxol (paclitaxel). Holton’s research enabled large-scale production of Taxol, transforming cancer treatment and saving countless lives.[1] He was a professor of chemistry at Florida State University (FSU) and is widely recognized for achieving the first total synthesis of Taxol, a landmark accomplishment in synthetic organic chemistry.[1]
The son of Aaron T. and Marion (née Downing) Holton, Robert Holton was born in Fayetteville, North Carolina on January 26, 1944, and raised in Charlotte.[2][3][4] He was the son of Marion Downing Holton and Aaron T. Holton.[4] He earned his undergraduate degree in chemistry from the University of North Carolina at Chapel Hill, where he met his first wife, Juanita Bird.[4] After moving to Tallahassee, he earned his doctorate from Florida State University and welcomed his first son, Robert.[4]
Following postdoctoral work at Stanford University, during which time his second son, David, was born, Holton held faculty positions at Purdue University and Virginia Tech.[4] In 1986, he returned to FSU with his second wife, Marie E. Krafft, where they both held faculty appointments in the Department of Chemistry and Biochemistry. During this time they had a son together, Paul. Holton spent the remainder of his career at FSU.[1]
Scientific contributions
In the 1960s, researchers at the National Cancer Institute isolated paclitaxel from the bark of the Pacific yew tree, discovering its potent anti-cancer properties through microtubule stabilization.[5] However, natural extraction was limited and unsustainable. In 1989, Holton and his research team at FSU developed a groundbreaking semi-synthetic process using 10-deacetylbaccatin III—a more renewable precursor—enabling large-scale production of Taxol.[6] Bristol Myers Squibb commercialized the drug in the early 1990s.[6]
When Taxol received FDA approval in 1993, the National Cancer Institute called it “the most important cancer drug developed in the previous 15 years.”[5] More than a million patients have since been treated with it.[6] In 1994, Holton’s team achieved the first total synthesis of Taxol, marking a significant milestone in organic chemistry and the culmination of an international scientific race.[1]
Beyond Taxol, Holton’s group accomplished the total synthesis of several other complex natural products, including prostaglandin F₂α, narwedine, aphidicolin, taxusin, and hemibrevetoxin B.[1] He co-founded Taxolog, Inc. with colleague Lewis Metts to develop new taxane-based therapies for cancer and other diseases. Holton also served as the company’s chief scientific officer and was president and founder of MDS Research Foundation and Syncure, Inc.[1]
